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A B S T R A C T
Background
Exercise programmes are a relatively inexpensive, low-risk option compared with other more invasive therapies for leg pain on walking
(intermittent claudication (IC)).
Objectives
To determine the effects of exercise programmes on IC, particularly in respect of reduction of symptoms on walking and improvement
in quality of life.
Search methods
The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last search February 2008) and the Cochrane
Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2008, Issue 1.
Selection criteria
Randomised controlled trials of exercise regimens in people with IC due to peripheral arterial disease.
Data collection and analysis
Two authors independently extracted data and assessed trial quality.
Main results
Twenty-two trials met the inclusion criteria involving a total of 1200 participants with stable leg pain. Follow-up period was from two
weeks to two years. There was some variation in the exercise regimens used, all recommended at least two sessions weekly of mostly
supervised exercise. All trials used a treadmill walking test for one of the outcome measures. Quality of the included trials was good,
though themajority of trials were small with 20 to 49 participants. Fourteen trials compared exercise with usual care or placebo; patients
with various medical conditions or other pre-existing limitations to their exercise capacity were generally excluded.
Compared with usual care or placebo, exercise significantly improved maximal walking time: mean difference (MD) 5.12 minutes
(95% confidence interval (CI) 4.51 to 5.72;) with an overall improvement in walking ability of approximately 50% to 200%; exercise
did not affect the ankle brachial pressure index (ABPI) (MD -0.01, 95% CI -0.05 to 0.04). Walking distances were also significantly
improved: pain-free walking distance MD 82.19 metres (95% CI 71.73 to 92.65) and maximum walking distance MD 113.20 metres
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(95% CI 94.96 to 131.43). Improvements were seen for up to two years. The effect of exercise compared with placebo or usual care
was inconclusive on mortality, amputation and peak exercise calf blood flow due to limited data.
Evidence was generally limited for exercise compared with surgical intervention, angioplasty, antiplatelet therapy, pentoxifylline, iloprost
andpneumatic foot and calf compressiondue to small numbers of trials and participants. Angioplastymay produce greater improvements
than exercise in the short term but this effect may not be sustained.
Authors’ conclusions
Exercise programmes were of significant benefit compared with placebo or usual care in improving walking time and distance in selected
patients with leg pain from IC.
P L A I N L A N G U A G E S U M M A R Y
Exercise for reducing intermittent claudication symptoms
Intermittent claudication is a cramping leg pain that develops when walking and is relieved with rest. It is caused by inadequate blood
flow to the legmuscles because of atherosclerosis (fatty deposits blocking blood flow through the arteries). People with mild-to-moderate
claudication are advised to keep walking, stop smoking and reduce cardiovascular risk factors. Other treatments include antiplatelet
therapy and pentoxifylline, angioplasty (inserting a balloon into the artery to open it up) and bypass surgery.
The present review shows that exercise programmes clearly improve walking time and distance for people considered fit for exercise
regimens. This benefit appears to be sustained over two years. The review authors identified 22 controlled trials that randomised some
1200 adults with stable leg pain to exercise, usual care or placebo, or the other interventions. Outcomes were measured at times ranging
from 14 days to two years. The types of exercise varied from strength training to polestriding and upper or lower limb exercises, in
generally supervised sessions, at least twice weekly. Compared with usual care, exercise therapy improved maximal walking time on a
treadmill by some 5 minutes (range 4.5 to 5.7 minutes) in a total of 255 participants. Pain-free walking distance was increased overall
by 82.2 metres (range 71.7 to 92.7) and the maximum distance participants could walk by 113.2 metres (range 95.0 to 131.4) in six
trials. Exercise did not improve ankle to brachial blood pressure index. No data were given on non-fatal cardiovascular events; data on
deaths and amputation were inconclusive.
Comparisons of exercise with surgical intervention, angioplasty, antiplatelet therapy, pentoxifylline, iloprost and pneumatic foot and calf
compression were limited because of small numbers of trials and participants. Exercise programmes are relatively inexpensive and low
risk compared with other more invasive therapies for improving leg pain on walking and related quality of life. People with intermittent
claudication are often elderly and have other pre-existing medical conditions, which would compromise an exercise programme or
make it impractical.
B A C K G R O U N D
Peripheral arterial disease is an important cause of morbidity and
mortality for people in many Western countries. It is estimated
that most adults have some degree of atherosclerosis by the time
they reach middle age, and that approximately 4% will have in-
termittent claudication (Leng 1993). Risk factors for the develop-
ment of lower limb arterial disease are similar to those for coro-
nary heart disease and include smoking, raised cholesterol levels,
hypertension and diabetes. Several epidemiological studies have
also demonstrated an association between sedentary habits and
increased risk of claudication (Leng 1993).
Treatment options for intermittent claudication include bypass
surgery, angioplasty and drug therapy but the mainstay of treat-
ment for many patients with mild-to-moderate claudication re-
mains as advice to ’stop smoking andkeepwalking’ (Housley 1988)
in addition to modification of cardiovascular risk factors. Numer-
ous studies of exercise therapy have been conducted using various
regimens that differed in duration and intensity; many of these
studies suggested that exercise can benefit patients with intermit-
tent claudication (Ernst 1992). Underlying mechanisms through
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which exercise may mediate an improvement include an increased
and more effective distribution of blood flow to the legs (Ernst
1982), improved rheological characteristics of the blood (Ernst
1987b), less reliance on anaerobic metabolism (Ruell 1984) and a
greater use of oxygen (Dahllof 1974b).
A meta-analysis of exercise rehabilitation programmes for claudi-
cation pain demonstrated that exercise training to near-maximal
pain for at least six months was beneficial in improving claudi-
cation (Gardner 1995). That review provided good evidence for
the best type of exercise therapy but did not compare the findings
with non-exercised control groups. The present Cochrane analysis
has concentrated on randomised controlled trials (RCTs) only and
has encompassed additional end points. If exercise proves to be a
beneficial treatment, more exercise programmes should be made
available for people with intermittent claudication as they may
represent a relatively cheap, low-risk option compared with other
more invasive therapies.
O B J E C T I V E S
The prime objective of this review was to determine whether an
exercise programme in people with intermittent claudication was
effective in alleviating symptoms and increasing walking distances
and times. Secondary objectives were to determine whether exer-
cise was effective in preventing deterioration of underlying disease,
reducing cardiovascular events and improving quality of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of an exercise regimen
versus control, or versusmedical or surgical therapy,were included.
Trials which used alternation (for example allocation by date of
birth or days of the week) were excluded; trials that were not
analysed on an intention-to-treat basis were included provided all
randomised patients were accounted for. For this update, trials
where numerical data in a usable format were not available, despite
contacting the authors, but which were otherwise suitable were
excluded.
Types of participants
Trials involving participants with intermittent claudication due to
atherosclerotic disease were included (diagnosed either by ques-
tionnaire or clinically). Studies of participants with asymptomatic
lower limb atherosclerosis that was identified by testing were ex-
cluded.
Types of interventions
Any exercise programme used in the treatment of intermittent
claudication, including walking, skipping and running. Inclusion
of trials was not affected by the duration, frequency or intensity of
the exercise programme but these issues were taken into account
in the meta-analysis. This review did not consider supervised ver-
sus unsupervised exercise because this is the subject of another
Cochrane review Bendermacher 2006.
Types of outcome measures
The prime outcome measure was treadmill walking distance (time
to onset of pain, maximal walking distance).
The following outcome measures were also considered: mortality;
cardiovascular events; direct measurement of disease progression
(for example using angiography, duplex ultrasound); indirect tests
of disease (for example ankle pressure measurements); and subjec-
tive measures (for example symptom progression, quality of life).
Search methods for identification of studies
The Cochrane Peripheral Vascular Diseases (PVD) Group
searched their Specialised Register (February 2008) and the
Cochrane Central Register of ControlledTrials (CENTRAL) (The
Cochrane Library 2008, Issue 1) using the search strategy shown
in Appendix 1 for publications describing (or which might de-
scribe) RCTs of exercise therapy in intermittent claudication.
The PVD Group Specialised Register is compiled from electronic
searches of MEDLINE (1966 to date), EMBASE (1980 to date)
and CINAHL (1982 to date) and through handsearching relevant
journals. The full list of journals that have been handsearched,
as well as the search strategies used, are described in the ’Search
strategies for the identification of studies’ section of the editorial
information about the Cochrane PVDGroup in The Cochrane Li-
brary, http://www.mrw.interscience.wiley.com/cochrane/clabout/
articles/PVD/frame.html.
In addition, trials were identified from references in a published
meta-analysis of exercise therapy (Gardner 1995), in reports of
exercise trials and by direct contact with principal investigators of
trials (wherever possible).
Data collection and analysis
For the update, one of the authors identified possible trials and
their eligibility for inclusion in the review was checked by another
author. Additional information was sought from trial authors, as
necessary, for all trials that appeared to meet the inclusion criteria.
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Quality of included trials was determined primarily by method
of allocation concealment, as described by Schultz (Schulz 1995);
blinding and by losses to follow up. In the original review, trials
were also assessed for internal and external validity using amodified
standard scoring sheet developed by the PVD group and evaluated
using the Chalmers method of quantitative evaluation (Chalmers
1981). For the update we scored all trials, including those in the
original review, using Jadad criteria (Jadad 1996).
Data were extracted independently by at least two of the authors.
Disagreements were resolved by discussion and the final results
were included in the review.
Heterogeneity between trial results was tested subjectively by clin-
ical judgement of differences in patient populations, interventions
(including type, duration and intensity of exercise programmes)
and outcome assessments. Heterogeneity was also assessed statis-
tically using the chi-squared test. Where appropriate, trial results
were pooled in a statistical meta-analysis using guidelines pub-
lished by the PVD group. Continuous data were analysed by de-
termining mean difference, using both fixed-effect and random-
effects models. Dichotomous data were analysed by determining
the risk ratio using a fixed-effect model, unless heterogeneity was
suspected.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Originally 10 trials were included, however for this update the
number rose to 22. In many cases trials were reported in two
or more publications. Some trials were excluded because relevant
numerical datawere not available. This included one of the original
trials (Holm 1973).
In total the number of participants increased from almost 250
to over 1200. Exercise was compared to seven different modes of
treatment, the most common being usual care or placebo. Fifteen
trials had less than 50 participants and two trials had over 100
(Gelin 2001; Zwierska 2005).
Two early trials compared exercise with placebo tablets (Dahllof
1974b; Larsen 1966) but in more recent studies usual care was
used as the control comparator. Exercise was compared with the
following drug therapies: antiplatelet agents (Mannarino 1991);
pentoxifylline (Ciuffetti 1994) and iloprost (Arosio 2001). Two
trials compared exercise with surgical intervention (Gelin 2001;
Lundgren 1989). Gelin 2001 used a three-way randomisationwith
usual care and compared surgery or an endovascular procedure,
depending on angiographic findings, rather than surgery alone. Of
76 participants in the surgery arm of the trial, 15 were considered
unsuitable for an invasive procedure with 17 patients receiving
angioplasty; therefore it is difficult to make direct comparisons
between the two studies.
Two trials compared exercise and angioplasty (Creasy 1990;Hobbs
2006). Tisi 1997 also included an exercise versus angioplasty com-
parison but only eight of the 28 patients randomised to receive
this intervention actually did. No results for this comparison have
been published other than the quality of life data. The exercise
versus angioplasty arm of this trial (Tisi 1997) has therefore not
been included in the review. One study compared exercise with
pneumatic foot and calf compression (Kakkos 2005).
Inclusion and exclusion criteria varied widely but usually those
people with serious co-morbidities which would compromise an
exercise programme, or make it impractical, were excluded.
There was some variation in the exercise regimens used, although
all recommended at least two sessionsweekly. All specified some el-
ement of supervision, except the earliest trial (Larsen 1966) where
patients were simply advised to exercise at home; and involved
some training or walking regimen. The duration of treatment gen-
erally fell within three to 12 months. The types of exercise varied
from strength training to polestriding, cycling and upper or lower
limb exercises. Outcomes were measured at times ranging from
14 days to 2 years. Compliance with exercise was variable and was
low at 49% in one trial (Gelin 2001).
Nearly all trials used a treadmill walking test to assess one of the
outcome measures, but there was considerable variation in out-
comes. Some reported walking distance, others reported walking
times. Calf blood flow and ankle brachial pressure index (ABPI)
were reported and often haematological and biochemical measures
were given. There was little information about mortality, ampu-
tations and fatal or non-fatal cardiovascular events. Six studies re-
ported quality of life and functional measures. As these were mea-
sured on a variety of different scales they were not included in the
meta-analysis but are shown in Table 1.
Additional information was sought from trialists of the majority
of the included studies.
Risk of bias in included studies
All studies were randomised controlled trials but in many reports
no details were available on the method of allocation other than a
statement of “randomised”. Trials which had high concealment of
allocation scores (A) were: Ciuffetti 1994; Hiatt 1994; Lundgren
1989; Collins 2005; Gelin 2001; Hobbs 2005; Hobbs 2006;
Kakkos 2005; Sanderson 2006; and Zwierska 2005.
All studies, including the original included trials, were scored using
Jadad criteria. Jadad scores varied from 1 to 3 as blinding was
generally not employed. Inevitably in trials of exercise blinding
was not possible; therefore, significant placebo responses may have
occurred in trials comparing exercise with usual care.
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There were either no or minimal loses to follow up in most tri-
als. In the largest trial (Gelin 2001) movement between the three
arms (exercise, surgery and usual care) was allowed within the trial
design; of 253 participants, 39 were lost to follow up at 1 year and
90 did not receive the treatment allocated, although results were
given on an intention-to-treat basis.
Effects of interventions
Exercise regimen compared with placebo or usual
care
Maximal walking time: Analysis 1.1
For 255participants therewas a highly statistically significant over-
all improvement in walking time (MD 5.12 min, 95% CI 4.51
to 5.72; fixed-effect model). The results were similar when calcu-
lated by the random-effects model (MD 5.17 min, 95% CI 4.05
to 6.29). Sanderson 2006 employed a combination of cycling and
treadmill training, which may account for the lack of effect seen in
this trial compared to the others.The walking time improvement
in the other six trials ranged from 50% to over 200%, which is
likely to be of clinical significance.
Pain-free walking time: Analysis 1.2
Two studies reported similar improvements for the exercise groups
(MD 2.91 min, 95% CI 2.51 to 3.31) using a fixed-effect model.
This was a 100% improvement, which is likely to be of clinical
significance.
Ankle brachial pressure index (ABPI): Analysis 1.3
The seven trials included in the meta-analysis uniformly showed
no change in ABPI (MD -0.01, 95% CI -0.05 to 0.04) using a
fixed-effect model.
Exercise calf blood flow: Analysis 1.4
The meta-analysis showed no significant overall improvement in
blood flow (MD 0.94 ml/100 ml/min, 95% CI -0.81 to 2.69;
fixed-effect model). Using a random-effects model the MD was
1.90 ml/100 ml/min (95% CI -1.21 to 5.01).
Pain-free walking distance: Analysis 1.5
Six trials were included and a significant improvement was seen
(MD 82.19 m, 95% CI 71.73 to 92.65; fixed-effect model). The
smallest study (Hobbs 2006) showed least effect and using a ran-
dom-effects model the MDwas 74.82 m (95% CI 45.9 to 103.7).
Excluding this study the improvement seen was 75% to 200%,
which is likely to be clinically significant.
Maximum walking distance: Analysis 1.6
Six trials reported this outcome and there was significant statistical
heterogeneity. The overall result was a statistically significant im-
provement (MD113.2 m, 95%CI 94.96 to 131.43) using a fixed-
effect model and a MD of 115.96 m (95% CI 26.67 to 205.26)
using a random-effects model. Improvements of up to 100% were
seen, which is likely to be clinically significant.
Amputation: Analysis 1.7
One trial (Gelin 2001) reported on amputation but only two
events occurred. The difference between groups was not signifi-
cant (RR 0.20, 95% CI 0.01 to 4.15).
Mortality: Analysis 1.8
One study (Gelin 2001) reported this outcome but there was no
significant difference between groups.
Exercise regimen compared with surgery
Two trials compared exercise with surgery (Gelin 2001; Lundgren
1989) (see comments in ’Description of studies’ above).
Maximal walking time: Analysis 2.1
Lundgren 1989 found no significant difference between the exer-
cise and surgery groups (MD -1.66 min, 95% CI -4.55 to 1.23).
Maximum walking distance: Analysis 2.2
In Gelin 2001 there was a significant improvement in walking
distance in the surgery group compared to exercise with a MD of
-97 m (95% CI -142.74 to -51.26), an improvement of 40%.
Ankle brachial pressure index (ABPI): Analysis 2.3
There was a significant improvement in ABPI in the surgery group
compared with those receiving exercise in Lundgren 1989 (MD -
0.27, 95% CI -0.37 to -0.17).
Exercise calf blood flow: Analysis 2.4
In Lundgren 1989 there was no significant difference between the
exercise and surgery groups at the end of the study (MD -2.70 ml/
100 ml/min, 95% CI -6.47 to 1.07).
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Amputation: Analysis 2.5
Gelin 2001 reported one amputation in the control group, the
result was not significant (RR 0.33, 95% CI 0.01 to 7.98).
Mortality: Analysis 2.6
Lundgren 1989 reported two deaths in the surgery group and
Gelin 2001 reported five deaths in each group. There was no
significant difference (RR 0.74, 95% CI 0.25 to 2.17).
Adverse events:
These included (Lundgren 1989) three wound haematomas,
thrombectomies and three participants required a further recon-
struction; the overall complication rate following surgery was
therefore 18%. There were no direct complications of exercise al-
though two participants developed worsening ischaemia and re-
quired surgery. In Gelin 2001 patency of reconstructions at one
year were 89% for supra-inguinal sites and 76% for infra-inguinal
sites, although further details of complications were not given.
Exercise regimen compared with angioplasty (PTA)
Two trials investigated this comparison. Creasy 1990 gave out-
comes at one year and Hobbs 2006 gave outcomes at six months.
Maximal walking time: Analysis 3.1
In Creasy 1990 walking time showed an initial increase in the an-
gioplasty group so that after six months it was higher than in the
exercise group, but not significantly so. Walking time then grad-
ually declined in the PTA group compared with a steady increase
in the exercise group so that after 12 months it was significantly
longer in those receiving exercise therapy (MD 3.30 min, 95% CI
2.21 to 4.39). This involved a doubling of mean walking time in
the exercise group.
Ankle brachial pressure index (ABPI): Analysis 3.2
After 12 months, the ABPI did not differ significantly between
the two groups (Creasy 1990). In the exercise group the ABPI was
relatively constant throughout the 12 month period, whereas in
the PTA group the mean resting ABPI increased significantly in
the first three to nine months (P < 0.01) but then subsequently
declined. The results at six months (Hobbs 2006) were better in
the angioplasty group giving an overall combined MD of -0.15
(95% CI -0.19 to -0.10) which is a statistically significant effect
although the difference in timing of these results must be noted.
Furthermore the heterogeneity between the trials was significant
(P<0.00001; I2 =96%) which may be related to the very small
numbers of patients and trials.
Pain-free walking distance: Analysis 3.3
In the small study of Hobbs 2006 a dramatic improvement was
seen in the angioplasty group (MD -542.80 m, 95% CI -815.43
to -270.17).
Maximum walking distance: Analysis 3.4
In Hobbs 2006 a significant increase was seen in the angioplasty
group (MD -436.6 m, 95% CI -797.88 to -75.32 m).
Mortality: Analyis 3.5
There were six deaths in the treatment group and four in the
control group (Creasy 1990) but this was not significant (RR 1.73,
95% CI 0.55 to 5.47).
Adverse events:
In the PTA group (Creasy 1990), two angioplasties were not suc-
cessful (one due to failure to pass a guide wire across a stenosis
in the superficial femoral artery, the other due to thrombosis of
the superficial femoral artery following angiography). There were
four complications: three groin haematomas, all treated conserva-
tively, plus a rupture of an external iliac artery requiring an emer-
gency ilio-femoral graft. One other patient had an elective aorto-
bifemoral graft for deterioration six months after the PTA. There
were no adverse events in the exercise group although one patient
requested PTA after three months because maximal walking dis-
tance had increased only marginally. Hobbs 2006 did not report
any serious side effects.
Exercise regimen compared with antiplatelet therapy
In the one trial which compared exercise with antiplatelet therapy
(Mannarino 1991) the following results were reported.
Maximal walking time: Analysis 4.1
After six months treatment maximal walking time was signifi-
cantly greater in the exercise group than for those treated with
antiplatelets (MD 1.06 min, 95% CI 0.15 to1.97). Maximum
walking time was increased by 86% in the exercise group and by
38% in those on antiplatelet therapy.
Ankle brachial pressure index: Analysis 4.2
There was no significant difference between the exercise and an-
tiplatelet therapy groups at the end of the trial (MD 0.00, 95%
CI -0.22 to 0.22).
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Exercise calf blood flow: Analysis 4.3
There was no significant difference in calf blood flow between
antiplatelet therapy and exercise groups after six months, although
flow tended to be higher in the exercise group (MD 2.18 ml/100
ml/min, 95% CI -0.28 to 4.64).
Exercise regimen compared with pentoxifylline
In the one trial which compared exercise with pentoxifylline (
Ciuffetti 1994) the following results were reported.
Maximal walking time: Analysis 5.1
After 13 weeks therapy, maximal walking time was significantly
greater in the pentoxifylline group than the exercise group (MD -
0.45 min, 95% CI -0.66 to -0.24). Walking distance increased by
62% in the exercise group and by 88% for those on pentoxifylline.
Adverse events:
Two patients experienced gastroenteritis during treatment with
pentoxifylline but this was not considered to be a side effect of
treatment.
Exercise regimen compared with iloprost therapy
Arosio 2001 investigated this comparison.
Pain free walking distance: Analyisis 6.1
There is a significant improvement in pain free walking distance
(MD 188.7 m, 95% CI 15.38 to 362.02)
Maximum walking distance: Analysis 6.2
There was a non-significant increase in this measure in the exercise
group (MD 196.80 m, 95% CI -83.8 to 477.40).
Exercise regimen compared with pneumatic foot and
calf compression
Kakkos 2005 described this comparison.
Pain-free walking distance: Analysis 7.1
Therewas a non-significant increase in the pneumatic compression
group (MD -160.30 m, 95% CI -438.88 to 118.28).
Maximum walking distance: Analysis 7.2
There was a non-significant slight increase in the pneumatic com-
pression group (MD -61.90 m, 95% CI -391.59 to 267.79).
D I S C U S S I O N
The data presented in this update generally confirms the find-
ings of the previous review, that exercise has a significant positive
effect on walking times and walking distances in people consid-
ered to be fit for exercise intervention compared to placebo or
usual care. While most studies examined outcomes at three or six
months, importantly this benefit would appear to be sustained
for up to two years (Jansen 1991). Mean improvements in walk-
ing distance and walking time with exercise were clinically and
statistically significant, however, in most cases the data were not
normally distributed. Some individuals responded with improve-
ments of considerably larger magnitude than the mean whereas
others responded less well, which may reflect varying compliance
with exercise programmes. Successful programmes generally com-
prised physiotherapy, supervised exercise two or three times per
week for 30-60 minutes, often with walking, leg exercises or tread-
mill training. Some encouraged additional home exercise.
The lack of effect of exercise on ABPI is also consistent. Data re-
lating to other important outcomes is more sparse as there were
no data on non-fatal cardiovascular events and inconclusive data
regarding mortality and amputation. The criteria for patient se-
lection excluded many patients with stable claudication for whom
exercise was not practical or safe due to pre-existing medical con-
ditions. As most patients with intermittent claudication are el-
derly, co-morbidities are common. For up to a third of patients
exercise may not be a suitable option. Other research and reviews
have examined the optimum modes of exercise regimen for those
with intermittent claudication; for example a Cochrane review
(Bendermacher 2006) explored supervised versus unsupervised ex-
ercise for intermittent claudication. The present review cannot re-
solve uncertainties about different exercise regimes although the
effect of cycling may not give the same benefits as other types of
exercise.
In one trial comparing exercise with surgery (Lundgren 1989),
ABPI significantly improved in the surgery group, compared with
exercise, and there was a non-significant increase in walking time
in the surgery group compared with exercise at 12 to 15 months.
The rapid benefit achieved by surgery must be weighed up against
the increased adverse events, however, surgical methods may have
changed since this trial. The more recent study (Gelin 2001) also
reported an increase in ABPI in the invasive treatment (surgery
or angioplasty) group compared with exercise at one year; with a
significant increase in walking distance in the invasive treatment
group compared with exercise. In constrast to other studies, this
trial found no improvement in walking distance in the arms com-
paring exercise to usual care, which may reflect the pragmatic de-
sign of the study and low compliance with exercise. It is, therefore,
difficult to compare this trial with others.
Data relating to exercise versus angioplasty are limited and recent
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trials have experienced difficulty in recruitment (Hobbs 2006a).
There would appear to be a greater improvement in walking time
and walking distance for those receiving angioplasty compared
with exercise in the first six months but the data from Creasy
1990 suggests that this may not be sustained at one year, indeed
the exercise group did significantly better at this time. The intial
improvement in ABPI, also noted at six months (Hobbs 2006),
was also not sustained in Creasy 1990. These trials are separated
in time by 16 years and it is possible that angioplasty techniques
have developed in sophistication over that time. The lack of data
regarding non-fatal cardiovascular events means that uncertainty
remains around whether exercise or invasive intervention alters
the propensity for cardiovascular events in other sites in patients
with intermittent claudication (Hobbs 2006; Hobbs 2006a). A
cost effectiveness study of exercise versus angioplasty found that a
twice weekly exercise programme was cost saving when outcomes
were measured at six months (Treesak 2004). Angioplasty versus
non-surgical management is the topic of another Cochrane review,
Fowkes 1996.
Antiplatelet therapy was less effective than exercise in improving
walking distance and other measures of lower limb function but
no data were presented in terms of fatal and non-fatal events. A
previous meta-analysis has shown antiplatelet agents to reduce the
incidence of cardiovascular events in patients with claudication
(Trialists 1994). Therefore, aspirin should be of benefit despite the
lack of effect on the lower limb.
The one small trial comparing pentoxifylline with exercise showed
participants on drug therapy to have significantly greater walk-
ing distances after three months than those on exercise therapy
(Ciuffetti 1994). There were no cardiovascular or adverse events
reported in those on pentoxifylline but disadvantages of drug treat-
ment might include cost and lack of general cardiovascular im-
provement. Arosio 2001 showed that exercise improved pain-free
walking time significantly more than iloprost, however this was a
small study (24 participants).
Pneumatic foot and calf compression gave non-significant im-
provements in walking distances compared with exercise, again
in a small trial (Kakkos 2005). This may be a promising area for
future investigation as people who are unsuitable for exercise pro-
grammes may be able to undertake this treatment.
Quality of life data were reported in a range of scales and this
made it difficult to incorporate into a meta-analysis. Results were
variable depending on the comparisons made and this is an area
for future research.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review suggests that exercise therapy should play an impor-
tant part in the care of selected patients with intermittent clau-
dication, to improve walking times and distances. Effects were
demonstrated following three months of supervised exercise al-
though some programmes lasted over one year. There are limited
data to suggest that an effect is sustained for up to two years. Fur-
ther information is required on the cost effectiveness of exercise
programmes.
Angioplasty may be more beneficial than exercise in improving
walking capacity in the short term but it is uncertain whether this
effect is sustained over 12 months. Evidence comparing exercise
and surgery is limited and it is difficult to draw firm conclusions.
Antiplatelet agents were less effective than exercise in improving
walkingdistance but should continue to be used because of benefits
in reducing cardiovascular events and death. In contrast, pentoxi-
fylline was more effective than exercise but may have fewer bene-
ficial effects on the cardiovascular system in general. Iloprost gave
less improvement in walking time than exercise. Pneumatic foot
and calf compression showed non-significant increases in walking
distances over exercise.
Implications for research
An important question is the degree of supervision required in
any exercise regimen and how long any change in exercise habits
can be expected to last. A trial is, therefore, required with a long
follow up, of five years, to compare the effectiveness of different
supervised and unsupervised regimens in changing long-term ex-
ercise patterns. Research should also focus on compliance with ex-
ercise and how this could be improved. Outcomemeasures should
include fatal and non-fatal cardiovascular events. Further cost-ef-
fective analysis is also required, to determine whether the cost of
supervised sessions might offset the cost of deterioration in terms
of surgery or occupation of inpatient beds for other complications
such as myocardial infarction.
Further research is required to determine the role of angioplasty
and surgery in the management of intermittent claudication, par-
ticularly to determine effects one or more years after the proce-
dure.
A trial is also required to compare exercise treatment with pentox-
ifylline to determine whether the benefit of drug treatment is sus-
tained over a longer period and whether there are any differences
in cardiovascular events. Further investigation of pneumatic foot
and calf compression in the treatment of intermittent claudication
is also needed. Consistency in use of quality of life measures in dif-
ferent trials would be helpful in linking the outcomes to patient-
assessed improvements.
A C K N OW L E D G E M E N T S
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Arosio 2001
Methods Study design: RCT. Method of randomisation: ’randomly divided’. Exclusions post-randomisation: not reported.
Losses to follow up: not reported. Jadad score: 1/5
Participants Country: Italy
Setting: hospital
No: 24
Age: mean 65 years; 64.5 (55-69) years in exercise group; 66.4 (57-72) years in iloprost group
Sex: all male
Inclusion criteria: Fontaine stage II PAOD with IC during past 4 to 6 years, confirmed by Doppler ultrasound,
angiography and ABI
Exclusion criteria: not clearly stated but inferred to be smoking, severe hypertension, stroke, ischaemic attack, cerebral
vascular disease, any drugs for PAODor other disease except transdermal clonidine for mild tomoderate hypertension
Interventions Intervention 1: physical exercise (n = 10) - walking, running, squat thrusts, 2 x day for 30 mins, cycle ergometer for
30 mins, plus 30 mins constant load treadmill (2 mph, slope 0%)
Intervention 2: iloprost (0.5-2 ng/kg/min) (n = 10)
Duration: 14 days
Outcomes Endogenous NO products, neutrophil adhesion, ICD, ACD (m) from constant load treadmill test
Notes Exercise was interrupted at onset of pain, participant rested for 3 min, or until pain had gone, then resumed activity
until each 30 min block was completed.
Information from authors - same study as Arosio 1999.
Ciuffetti 1994
Methods Study design: RCT.
Method of randomisation: allocated by pre-determined computer code. Not blinded
Exclusions post-randomisation:
Losses to follow up:
Jadad score: 3/5.
Participants Country: Italy
Setting:
No. of participants: 30
Age: 48-64 years
Sex: male and female
Inclusion criteria: stable maximal walking time (90-130 s) at 2 previous 6 monthly checks, plus stage II PAOD
confirmed by velocimetry and angiography
Exclusion criteria: no h/o vascular surgery, coronary or cerebrovascular disease, DM; no factors affecting oxygen
demand (eg anaemias); recent infections; treatment with vasodilators, antiplatelets, anticoagulants or drugs affecting
haemorrheological parameters for previous 1 mth
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Ciuffetti 1994 (Continued)
Interventions Treatment: 1 h exercise at home daily plus twice weekly supervision at outpatients. Home regimen: week 1, 500 m
in 20 min; week 2, 1000 m in 40 min; week 3, 2000 m in 60 min on the flat
Control: pentoxifylline 800 mg tds
Duration: 3 mths
Outcomes Primary: treadmill test maximal walking distance (2 km/h on 12 degree slope)
Notes
Collins 2005
Methods Study design: RCT.
Method of randomisation: states ’randomised’ but method not reported in this article (is reported in previous article
though)
Exclusions post-randomisation:
Losses to follow up: 6 (4 PS, 2 control).
Jadad score: 3/5.
Participants Country: USA
Setting: community
No: 52 (49 analysed)
Age: 65.8 ± 7.1 years polestriding group; 68.0 ± 8.6 control group
Sex: 51 M, 1 F
Inclusion criteria: history of IC, ABI < 0.95 at rest or < 0.85 after exercise, IC pain a factor for arrested walking
Exclusion criteria: vascular surgery, angioplasty in previous 6months, other co-morbid conditions that would interfere
with participation in an exercise programme, currently taking vitamin E, warfarin or pentoxifylline, unable to give
informed consent
Interventions Treatment: polestriding (n = 27) supervised training 3 times per week for 4 weeks, twice weekly for 8 weeks, once
weekly for 4 weeks, biweekly for 4 weeks, unsupervised for 4 weeks
Control: no exercise (n = 25) usual care. Seen biweekly for 3 months and monthly thereafter
Duration: 24 weeks
Outcomes Primary: ABPI, maximum walking distance, oxygen uptake
Secondary: health-related quality of life
Notes All participants given $6 travel for each visit and $5 for each test battery completed, starting at $25.
Secondary analysis of the 2 x 2 factorial design of Collins 2003 since there was no influence of vitamin E on exercise
they combined the exercise groups together and compared with the non-exercise groups. Also reported as Langbein
1998, 2002
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Creasy 1990
Methods Study design: RCT.
Method of randomisation: “Simple” randomisation method. Not blinded
Exclusions post-randomisation: not described.
Losses to follow up: at 6 years 19 of whom 10 had died, 2 had amputation, others uncontactable or too ill
Jadad score: 2/5.
Participants Country: England
Setting: university department
No. of participants: 36 (56 in Perkins paper and Creasy 1992)
Age: mean 62.9 years
Sex: male and female
Inclusion criteria: stable unilateral IC with failure of conservative treatment for >3 mths; treadmill walking distance
<375 m; lesion on angiogram suitable for PTA
Exclusion criteria: none stated.
Interventions Treatment: 30 min sessions of dynamic leg exercises twice weekly for first 6 mths, and on a regular basis afterwards
(supervised by physiotherapist); encouraged to exercise daily at home
Control: PTA by experienced radiologist using conventional guidewire and balloon catheter technique, producing
overdilation by ~10% more than normal, for at least 45 s with heparin cover
Duration: 12 mths, then at 6 years range 45-83 months
Outcomes Primary: treadmill test pain-freeMD and maximal walking distance (3 km/h at 10% incline).
ABPI.
Secondary: complications of treatment.
Also reported mortality with usable data in Perkins paper.
Notes Authors contacted for more information as 6 year results given as graphs but data no longer available. ICD and ACD
reported to be significantly greater for patients in exercise group, ABPI significantly increased in PTA group
Dahllof 1974
Methods Study design: RCT.
Method of randomisation: states “randomised”. Not blinded.
Exclusions post-randomisation:
Losses to follow up:
Jadad score: 2/5.
Participants Country: Sweden
Setting:
No. of participants: 18
Age: 54-71 years
Sex: male and female
Inclusion criteria: IC for >1 year
Exclusion criteria: DM or IHD
Interventions Treatment: 30 min training sessions 3 times weekly, supervised by a physiotherapist, including dynamic leg exercises
beyond the appearance of pain
Control: placebo tablets
Duration: 6 mths
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Dahllof 1974 (Continued)
Outcomes Primary: treadmill test pain-free and maximal walking distance (max. 1000 m), at 4 km/h
Secondary: calf blood flow - venous occlusion plethysmography after ischaemic foot exercises
Notes
Gardner 2002
Methods Study design: RCT.
Method of randomisation: not described.
Exclusions post-randomisation: nil.
Losses to follow up: 3 in treatment group, 6 in control group dropped out. More at 18 months - 31 remained
Jadad score: 2/5.
Participants Country: US
Setting: vascular clinics, newspaper and radio adverts
No. of participants: 61 originally, 31 remained at 18 months
Age: over 60 years
Sex: 90% male
Inclusion criteria: Fontaine II PAOD Rose questionnaire.ABPI <0.97 at rest. IC limiting factor on treadmill
Exclusion criteria: other significant medical conditions limiting exercise tolerance, poorly controlled DM
Interventions Treatment: 30 min training sessions 3 times weekly for 6 months then twice weekly for 12 months
Control: usual care
Duration: 6 months and 18 months
Outcomes Treadmill distance to claudication
maximum claudication distance
ABPI
peak oxygen uptake
walking economy
6-minute walking distance
accelerometer derived physical activity
walking impairment questionnaire
calf blood flow
health-related quality of life on SF-36
self-perceived ambulatory measures.
Notes
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Gelin 2001
Methods Study design: RCT.
Method of randomisation: block, computer.
Exclusions post-randomisation: nil stated.
Losses to follow up: 39 (13 control, 15 training, 11 invasive therapy) did not complete evaluation at 1 year. A total
of 90 patients did not complete treatment as allocated, although analysis was based on intention to treat. 15 were
unsuitable for surgery and 17 recieved angioplasty in surgery arm
25 withdrew from quality of life section.
Jadad score: 3/5.
Participants Country: Sweden
Setting: vascular outpatients
No: 253
Age: mean 67 (range 45-81) years
Sex: 67% male
Inclusion criteria: stable intermittent claudication for > 6 months, ABI < 0.6. Maximum post-ischaemic blood flow
< 25 ml/min/100g, willing to undergo operations
Exclusion criteria: contraindication to surgery; other disorder limiting treadmill walking
Interventions Treatment:
1. supervised exercise training 30 min 3 times per week for 6 months then 6-12 months 2 sessions per week;
2. invasive surgery/endovascular procedure, based on angiographic findings
Control: observation only
Duration: 1 year
Outcomes Primary:
mortality, ABI, amputation, treadmill distance;
max post-ischaemic calf blood flow;
big toe systolic pressure.
Secondary:
blood pressure;
haemoglobin, cholesterol, triglycerides, creatine;
quality of life.
Notes Quality of life (data for 171 only, 18 changed group but were analysed in original).
Randomised before pre-treatment investigations. Low compliance in exercise group but classes offered for longer
than most studies.
Results for ABPI omitted standard deviations.
Hiatt 1990
Methods Study design: RCT.
Method of randomisation: randomised in sealed envelopes in pairs matched by ABPI and walking distance. Not
blinded
Exclusions post-randomisation:
Losses to follow up: 6 in treatment group and 2 in control.
Jadad score: 2/5.
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Hiatt 1990 (Continued)
Participants Country: USA
Setting:
No. of participants: 29
Age: mean 67 years
Sex: all male
Inclusion criteria: IC due to PAOD (ABPI <0.95 at rest or <0.85 after exercise)
Exclusion criteria: critical limb ischaemia; unable to walk on the treadmill; DM; vascular intervention in previous
year; treatment with beta blockers or pentoxifylline
Interventions Treatment: programme of exercise 3 times each week (5 min warm up, 50 min intermittent isotonic, resistive exercise,
5 min cool down)
Control: maintain usual level of exercise
Duration: 12 weeks
Outcomes Primary: treadmill test maximal walking time (2 mph at 0% slope, with a subsequent 3.5% increase in slope every 3
min until forced to stop)
Secondary: calf blood flow venous occlusion plethysmography.
Subjective indicators: perceived pain during exercise; walking-limited distance
Notes The Hiatt 1990 trial included distance walked and claudication pain. Unfortunately these results were not reported
by treatment group but simply correlated with treadmill performance. The correlation was good, therefore it may be
assumed that a significant improvement was experienced in those receiving exercise therapy
Hiatt 1994
Methods Study design: RCT.
Method of randomisation: sealed envelope. Not blinded.
Exclusions post-randomisation:
Losses to follow up: 2 in control group.
Jadad score: 2/5.
Participants Country: USA
Setting:
No. of participants: 29
Age: mean 60 years
Sex: male only
Inclusion criteria: 3 mth h/o stable IC (Rose questionnaire) limiting exercise sufficiently to affect ability to perform
routine activity; ABPI <0.94 at rest, <0.73 after exercise
Exclusion criteria: rest pain, ulcer, gangrene; unable to walk on treadmill at >2 mph; exercise limited by angina, CHF,
COAD or arthritis; no DM, vascular surgery or PTA in previous year
Interventions Treatment: either supervised treadmill walking exercise (n=10) or strength training (n=9), and encouraged to walk
alone for 2 days each week (treadmill - 1 h 3 times a week, walking until moderate pain, then rest)
Control: maintain usual level of activity
Duration: 12 weeks
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Hiatt 1994 (Continued)
Outcomes Primary: treadmill test pain-free and maximal walking distance (2 mph, 0% slope, with a subsequent 3.5% increase
in slope every 3 min until forced to stop).
ABPI (resting and post-exercise).
Notes Trial continued after 12 weeks without a control group, therefore later results not included.
Strength training was less effective than treadmill exercise, only the latter was included in the meta-analysis for
statistical reasons
Hobbs 2005
Methods Study design: RCT.
Randomisation: yes 2x2 factorial design, random number table
Concealment of allocation: yes.
Exclusions post-randomisation: not reported.
Losses to follow up: 4 of original 38 withdrew
Intention to treat: yes.
Jadad score 3/5.
Participants Country: UK
Setting: university department of vascular surgery, patients referred to IC clinic from primary or secondary care
No. of participants: 34
Age: median 67 (63-72) years
Sex: 27 men, 7 women
Inclusion criteria:
IC diagnosed by Edinburgh claudication questionnaire and reduced ABPI <0.9, reviewed after 3-6 months;
max walking distance 20-500 m.
Exclusion criteria:
significant aorto-iliac disease, unable to complete treadmill distance to absolute claudication distance, MI, transient
ischaemic attack, strole or PTA in last 3 months, CHF, bellding diathesis, glomerular filtration rate <20mL/min,
CYP3A4 or CYP2C19 inhibitor use
Interventions Treatment:
1. supervised exercise - 3 month, twice weekly 1 hour physiotherapist-led exercise programme. Given video tape of
programme and encourage to take log of exercise at home;
2. cilostazole 100mg twice daily, if side effects dosing halved for 1 week;
3. exercise as above plus cilastozole.
Control:
best medical therapy
Duration: 6 months
Outcomes Maximum walking distance
pain-freeMD walking distance
ABPI
thrombin anti-thrombin complex
prothrombin fragments 1 and 2
plasminogen activator inhibitor
tissue plasminogen activator.
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Hobbs 2005 (Continued)
Notes Authors contacted for means and SDs - received for best medical therapy and supervised exercise groups
Hobbs 2006
Methods Study design: RCT.
Randomisation: random number table.
Concealment of allocation: yes.
Exclusions post-randomisation: not reported.
Losses to follow up: not reported.
Intention to treat: yes.
Jadad score 3/5.
Participants Country: UK
Setting: university department of vascular surgery, patients referred to IC clinic from primary or secondary care
No. of participants: 23
Age: median 67 (57-77) years
Sex: 15 men, 7 women
Inclusion criteria:
IC diagnosed by Edinburgh claudication questionnaire and reduced ABPI <0.9, reviewed after 3-6 months;
max walking distance 20-500 m.
Exclusion criteria:
significant aorto-iliac disease, unable to complete treadmill distance to absolute claudication distance, MI, transient
ischaemic attack, stroke or PTA in last 3 months, CHF, bellding diathesis, glomerular filtration rate <20mL/min,
CYP3A4 or CYP2C19 inhibitor use
Interventions Treatment:
1. supervised exercise - 3 month, twice weekly 1 hour physiotherapist-led exercise programme. Given video tape of
programme and encourage to take log of exercise at home;
2. PTA.
Control:
best medical therapy
Duration: 6 months
Outcomes Maximum walking distance
pain-freeMD walking distance
ABPI
thrombin anti-thrombin complex
plasminogen activator inhibitor
tissue plasminogen activator.
Notes Authors contacted for means and SDs - received.
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Jansen 1991
Methods Study design: RCT.
Method of randomisation: not described.
Exclusions post-randomisation: not described.
Losses to follow up: not described.
Jadad score: 1/5.
Participants Country: Germany
Setting: community
No: 48
Age: not described
Sex: not described
Inclusion criteria: PAOD stage II
Exclusion criteria: not stated
Interventions Treatment: training on treadmill 3.5 km/hr 10% slope for 2 hours twice per week under medical/physiotherapy
supervision
Control: no training
Duration: 2 years
Outcomes Primary:
treadmill walking distance, pain-free and maximum.
Secondary:
ultrasound Doppler of arm and leg arteries.
Notes
Kakkos 2005
Methods Study design: RCT.
Method of randomisation: “blind block telephone procedure” by means of computer
Exclusions post-randomisation:
Losses to follow up: 4 in supervised exercise group; 4 in pneumatic compression group
Jadad score: 3/5 (for now).
Participants Country: England
Setting: vascular outpatients clinic
No: 34
Age: median and IQR: 66 (10.5) unsupervised exercise group; 69 (11.8) supervised exercise group; 66 (7) intermittent
pneumatic compression group
Sex: 27 M in total; 8 M USE group, 11 M SE group, 8 M IPC group
Inclusion criteria: stable IC for > 6 months due to SFA occlusion of = 6 cm on ultrasound or angiogram
Exclusion criteria: duration of symptoms < 6 months, previous angioplasty or arterial surgery to symptomatic leg,
myocardial infarction within previous 6 months, inability to manage treadmill or training, any psychiatric illness
or other reason making follow-up difficult, ischaemic rest pain, gangrene, ischaemic ulceration, unable to attend
supervised programme, severe peripheral neuropathy, ABPI > 0.9 at enrolment, non-compressible calf arteries, iliac
occlusions or stenoses amenable to surgery or angioplasty, femoral artery occlusion < 6 cm, exercise capacity limited
by angina, congestive heart failure, COPD, disease of spinal column, venous disease, neurological disease, mental
illness or arthritis
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Kakkos 2005 (Continued)
Interventions Treatment: supervised (n = 12) or unsupervised exercise (n = 9): constant load treadmill at 10% gradient, 3.5 km/hr
Control: pneumatic foot compression (n = 13)
Duration: 6 months treatment period plus further follow up at 12 months after treatment began (exercise advice
given for second 6 month period)
Outcomes Primary: ICD, ACD, ABPI
Secondary: SF-36, walking impairment questionnaire (WIQ), IC questionnaire
Notes The authors contacted successfully for means and SDs.
Larsen 1966
Methods Study design: RCT.
Method of randomisation: randomised in pairs matched by age and disease. Not blinded
Exclusions post-randomisation:
Losses to follow up:
Jadad score: 2/5.
Participants Country: Denmark
Setting:
No. of participants: 14
Age: 44-65 years
Sex: male and female
Inclusion criteria: typical IC, stable for >6 mths
Exclusion criteria: none stated
Interventions Treatment: instructed to walk daily, in addition to normal activities
Control: 1 placebo (lactose) tablet bd
Duration: 6 mths
Outcomes Primary: treadmill test maximal walking distance (4.6 km/h, elevation of 0, 8 or 16 cm/m)
Secondary: calf blood flow xenon clearance method.
Notes
Lundgren 1989
Methods Study design: RCT.
Method of randomisation: randomised, balanced by age, sex and DM. Not blinded
Exclusions post-randomisation: not stated.
Losses to follow up: surgery not performed in 2 participants; exercise not carried out in 4
Jadad score: 2/5.
Participants Country: Sweden
Setting: not stated
No. of participants: 50
Age: 40-80 years
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Lundgren 1989 (Continued)
Sex: male and female
Inclusion criteria: IC >6 mths; maximal walking distance <600 m; BP in first toe >30 mmHg
Exclusion criteria: rest pain or ulcer
Interventions Treatment: dynamic leg exercises beyond appearance of pain, supervised by physiotherapist, 30 min sessions 3 times
each week; encouraged to exercise at leisure
Control: surgical intervention, including thrombendarterectomy, bypass with synthetic y-graft, saphenous vein or
polytetrafluoroethylene graft
Duration: 12-15 mths
Outcomes Primary: treadmill test pain-free and maximal walking distance (4 km/h at 0 slope to maximum of 1000 m);
ABPI.
Secondary: calf blood flow venous occlusion plethysmography.
Notes A third group of 25 participants received surgery combined with an exercise regimen. These results are not included
in formal meta-analysis
Mannarino 1991
Methods Study design: RCT.
Method of randomisation: states random. Not blinded.
Exclusions post-randomisation:
Losses to follow up: none.
Jadad score: 1/5.
Participants Country: Italy
Setting:
No. of participants: 20
Age: 48-75 years
Sex: male and female
Inclusion criteria: IC for >2 yrs, stable for past 3 mths, pain-free walking distance <300 m
Exclusion criteria: h/o angina, recent MI or stroke; vascular surgery or PTA in previous 6 mths; impaired cardiac or
lung function, major liver, kidney or metabolic disorders, infections, cancer or peptic ulcers
Interventions Treatment: 1 h home exercises daily supervised via out-patients. Week 1 - 500 m in 20 min; week 2 - 1000 m in 40
min; week 3 - 2000 m in 60 min
Control: dipyridamole 75 mg tds plus aspirin 330 mg od.
Duration: 6 mths
Outcomes Primary: treadmill test pain-free and maximal walking time (2 km/h on 12 degree slope);
ABPI.
Secondary: calf blood flow strain-gauge plethysmography.
Notes A third group of 10 participants received antiplatelet treatment and exercise. These results are discussed but not
formally included in a meta-analysis
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Mika 2005
Methods Study design: RCT.
Method of randomisation: not described
Exclusions post-randomisation: not described.
Losses to follow up: 18 withdrew (10 control, 8 exercise).
Jadad score: 2/5.
Participants Country: Poland
Setting: university department outpatient clinics
No. of participants: 98
Age: 50-70 years
Sex: male and female
Inclusion criteria: PAOD and IC (Fontaine stage II) stable for 3 months, pain-free walking distance 50-200 m at 3.
2 km/h
Exclusion criteria: angina, recent MI, vascular surgery in last 3 months, impaired cardiac or lung function, DM,
cancer, kidney and liver disease, arthritis limiting walking, other contraindication to walking, those taking beta
blockers, pentoxifylline or other haemorheologically active drugs
Interventions Treatment: 12 week programme of supervised pain-free treadmill exercise, 1 hour per day three times a week of
repetitive walking exercise
Control: usual care
Duration: 3 months
Outcomes Pain-free walking distance
total leucocyte count
neutrophil count
microalbuminuria.
Notes
Mika 2006
Methods Study design: RCT.
Method of randomisation: not described.
Exclusions post-randomisation: not described.
Losses to follow up: 5.
Jadad score: 2/5.
Participants Country: Poland
Setting: university department clinics
No. of participants: 60
Age: 50-70 years
Sex: male and female
Inclusion criteria: Fontaine stage II PAOD, IC limiting walking and stable for 3 months, ABPI <0.9
Exclusion criteria: angina, recent MI, vascular surgery in last 3 months, impaired cardiac or lung function, DM,
cancer, kidney and liver disease, arthritis limiting walking, unable to walk at 3.2 km/hour, those taking beta blockers,
pentoxifylline or other haemorheologically active drugs
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Mika 2006 (Continued)
Interventions Treatment: 12-week programme of supervised pain-freeMD treadmill exercise, 1 hour per day three times a week of
repetative walking exercise
Control: usual care
Duration: 3 months
Outcomes Pain-free walking time
maximum walking time
red cell deformability - erythrocyte elongation index.
Notes
Sanderson 2006
Methods Study design: RCT.
Blinded: no.
Exclusions post-randomisation: nil.
Losses to follow up: 1 in treadmill group.
Jadad score: 3/5.
Participants Country: Australia
No.of participants: 42
Age: mean 63 years
Inclusion criteria: claudication lasting > 1 year, ABPI < 0.9
Exclusion criteria: reduced cardiac function, rest pain, recent surgery or cardiac event, other medical conditions
rendering exercise unsuitable
Interventions Treatment:
1. treadmill exercise;
2. cycling.
Both groups exercised three times a week for 6 weeks
Control: no exercise
Duration: 6 weeks
Outcomes Maximal and pain-free walking and cycling tests
submaximal and peak physiological response
ABPI.
Notes Stratified by gender, presence of diabetes, then randomised
results given as mean differences, contact authors.
27Exercise for intermittent claudication (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tisi 1997
Methods Study design: RCT.
Method of randomisation: randomised by sealed envelope, weighted 70:40:40 (angioplasty:exercise:observation).
19/25 randomised to PTA had unsuitable lesions and the technique failed in one other. Not blinded.
Intention-to-treat analysis.
Exclusions post-randomisation:
Losses to follow up:
Jadad score: 1/5.
Participants Country: England
Setting: general hospital
No. of participants: 67
Age: mean 69.3 years
Sex: male and female
Inclusion criteria: stable IC >6 mths, positive Edinburgh Claudication Questionnaire, ABPI <0.8 and >30 mm Hg
drop in ankle systolic pressure on exercise, and walking distance 50-250 m on treadmill (3 km/hr, 10% gradient)
Exclusion criteria: intervention for IC in past 6 mths, exercise limited by other factors, concurrent medical disease,
treatment with steroids, or inability to complete assessment visits
Interventions Treatment:
1. exercise - series of active and passive leg exercises performed to the limit of exercise pain, supervised by a physio-
therapist once weekly for 4 weeks. Also encouraged to exercise for 45 min daily at home, plus to walk 1 mile a day;
2. PTA.
Control: observation, plus advice given to all 3 groups (leaflet advising on weight loss, smoking and exercise, plus 75
mg aspirin daily)
Duration 12 mths
Outcomes Primary: treadmill test: pain-freeMD and maximal walking distance (3 km/h on 10% slope);
ABPI.
Secondary: Nottingham Health Profile
Notes Results for the exercise vs angioplasty comparison have not been included in this review. This is because only a very
small proportion of patients randomised to PTA actually received this treatment, and because the only published
outcomes are for quality of life.
Claudication and walking distance results not in usable format
Tsai 2002
Methods Study design: RCT.
Method of randomisation: not described.
Exclusions post-randomisation: not described.
Losses to follow up: 11, 5 in treatment group.
Jadad score: 2/5.
Participants Country: Taiwan
Setting: community
No. of participants: 64
Age: 76 years +/- 4
Sex: 81% male
Inclusion criteria: Fontaine II PAOD on Rose questionnaire. ABPI <0.95
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Tsai 2002 (Continued)
Exclusion criteria: intervention for IC in past 3 mths, exercise limited by other factors, rest pain, MI or unstable
claudication in the last 3 months, history of angina on exertion
Interventions Treatment: 12 weeks progressive rehabilitiation programme, three times a week. Up to 30 minutes on the treadmill
Control: usual care
Duration 12 weeks
Outcomes Time to onset of pain
time to maximum pain
6-minute walking distance
walking impairment questionnaire
physical function
bodily pain
role limitation physical and emotional
general health
mental health
social function
vitality.
Notes
Zwierska 2005
Methods Study design: RCT.
Method of randomisation: randomisation was undertaken using the fishbowl technique (Baumgartner and Strong
1998). This involved drawing patient names out of a ’hat’ and allocating them to the respective groups at random .
Randomisation was undertaken by an independent academic based at another site in Sheffield
Intention-to-treat analysis: yes.
Exclusions post-randomisation: nil.
Losses to follow up: 10.
Jadad score: 2/5.
Exclusion criteria: not stated
Participants Country: UK
Setting: not stated
No. of participants: 104
Age: median 69 (50-89)
Sex: not stated
Inclusion criteria: stable symptomatic peripheral arterial disease
Exclusion criteria: not stated.
Interventions Treatment:
1. supervised upper limb aerobic exercise;
2. supervised lower limb aerobic exercise
Control:
no exercise.
Duration: 24 weeks
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Zwierska 2005 (Continued)
Outcomes Claudication distance
Maximum walking distance
peak heart rate
peak oxygen consumption
perceived exertion and pain
physical activity status.
Notes Results given as medians - authors contacted for more information, received
PAOD = peripheral arterial occlusive disease
IC = intermittent claudication
mth(s)= month(s)
h/o = history of
DM = diabetes mellitus
IHD = ischaemic heart disease
CHF = congestive heart failure
COAD = chronic obstructive airways disease
MI = myocardial infarction
tds = three times a day
bd = twice a day
od = once a day
PTA = percutaneous transluminal angioplasty
ABPI = ankle brachial pressure index
ICD = intermittent claudication distance
ACD = absolute claudication distance (or maximum walking distance)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Buchwalsky 1974 Two training groups.
Bulling 1991 Comparison of exercise plus gingko biloba and exercise versus placebo group. No non-exercise control group
Cachovan 1997 Two exercise groups.
Cachovan 1999 Comparison of two different sequences of exercise. No non-exercise control group
Carmeli 2004 Not randomised.
Cheetham 2004 Two exercise groups and no non-exercise control group.
Cina 1996 Comparison of physical training with low dose heparin and physical training and placebo. No non-exercise
control group
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(Continued)
Dahllof 1976 This trial was not fully randomised as the first ten of the 34 patients were allocated to exercise before ran-
domisation was introduced. There were also several differences between the treatment and control groups,
including significantly higher cholesterol levels and maximal calf blood flow in the control group. Treatment
effects may also have been masked because many control subjects spontaenously undertook increased exercise
during the trial period
Degischer 2002 Not a randomised trial and both groups had exercise.
Dittmar 1977 Exercise in addition to drug.
Ericsson 1970 This trial compared exercise with no treatment but was excluded from the review because of insufficient
evidence that patients were randomised. The paper stated that patients were “divided into two groups”, and
the trialists were approached to confirm the method of allocation. No reply was received, therefore it was
decided to exclude the results from the review, unless evidence becomes available to the contrary
Ernst 1987 This trial compared participants on an exercise programme with those not exercised but allocation was not
strictly randomised as patients were “assigned according to space on the exercise programme”
Ernst 1990 Comparison of treadmill exercise plus pentoxifylline and treadmill exercise plus placebo. No non-exercise
control group
Ernst 1997 Review of chelation therapy.
Fitzgerald 1971 This trial compared an exercise regimen with no treatment but there is no evidence in the report that the
groups were randomly allocated. The quality of the trial also appeared generally poor with a variable period
of follow up and the inclusion of some patients who did not have intermittent claudication
Fowler 2002 Some patients were asymptomatic and it was not possible to exclude these for the purposes of data extraction
Gardner 2005 Two exercise groups compared.
Gibbellini 2000 Satisfied inclusion criteria but no usable data despite attempting to contact authors. Results divided into
asymptomatic and symptomatic groups, not aggregated
Gottstein 1987 Both groups received training.
Holm 1973 Suitable for review (originally excluded) but no usable numerical data despite attempt to contact author. Stated
significant improvement in walking time in exercise group compared to placebo
Jones 1996 Comparison of treadmill versus stairmaster. No non-exercise control group
Kiesewetter 1987 Both groups received intensive physical therapy. No non-exercise control group
Krause 1976 Combines exercise with drug.
Labs 1999 Comparison of constant-load and graded-load treadmill testing with and without beraprost sodium. No non-
exercise control group
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(Continued)
Lee 2007 Non-randomised (clinical and cost-effectiveness).
Lepantalo 1984 Comparison of exercise plus flunarizine and exercise plus placebo. No non-exercise control group
Maejima 2005 Satisfied inclusion criteria but no data available after attempt to contact authors. Reported improvement in
walking time in exercise group at 12 weeks
Mannarino 1988 Controlled, not randomised.
Mannarino 1989 This trial compared an exercise regimen with nothing (placebo tablets) but the report suggested that the
groups were not allocated by an acceptable randomisation method. Trialists have been approached to confirm
the method of allocation, therefore it may become possible to include the trial at a later date
McDermott 2004 Patients did not have intermittent claudication.
Nawaz 1999 Both groups had exercise advice. No non-exercise control group
Nawaz 2001 Comparison of upper limb and lower limb exercise. Separate non-randomised control group
Necker 2001 Training after angioplasty.
Necker 2003 Training after angioplasty.
Nielsen 1975 Two exercise groups.
Nielsen 1977 Both groups had exercise. No non-exercise control group.
Patterson 1997 Comparison of supervised exercise programme plus lectures and home-based exercise plus lectures. No non-
exercise control group
Pinto 1997 Two exercise regimens.
Presern-Strukelj 200 Comparison of standard exercise alone and standard exercise plus electrostimulation in amputees with periph-
eral arterial occlusive disease
Riebe 2001 Comparison of two progressive treadmill tests. No non-exercise control group
Savage 2001 Compared supervised exercise versus home-based exercise. No non-exercise control group
Scheffler 1991 Each group received exercise training. No non-exercise control group
Schoneberger 1994 Controlled study, not randomised
Silvestro 2002 Age-matched control group.
Slordahl 2005 Two exercise groups.
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(Continued)
Streminski 1992 Satisfied inclusion criteria but data not available in usable format despite attempt to contact author. Actovegin
versus exercise. Results given as mean change. Reported improvement in pain-free walking distance in exercise
group
Taft 2004 This study was not truly randomised and did not contain any outcomes of relevance to this review
Thomson 1999 Two exercise groups.
Walker 2000 The non-exercise group was not randomised.
Waller 1988 Comparison of exercise where patients had smoked immediately prior to treadmill test and exercise where
patients had not smoked prior to treadmill test
Zwierska 2004 Both groups had exercise. No non-exercise control group.
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D A T A A N D A N A L Y S E S
Comparison 1. Exercise regimen compared with placebo/usual care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximal walking time (minutes) 7 255 Mean Difference (IV, Fixed, 95% CI) 5.12 [4.51, 5.72]
1.1 Usual care 6 241 Mean Difference (IV, Fixed, 95% CI) 5.12 [4.51, 5.72]
1.2 Placebo 1 14 Mean Difference (IV, Fixed, 95% CI) 5.13 [0.80, 9.46]
2 Pain free walking time (minutes) 3 150 Mean Difference (IV, Fixed, 95% CI) 2.91 [2.51, 3.31]
3 Ankle brachial pressure index 7 228 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.05, 0.04]
4 Peak exercise calf blood flow
(ml/100 ml/min)
4 103 Mean Difference (IV, Fixed, 95% CI) 0.94 [-0.81, 2.69]
4.1 Usual care 2 71 Mean Difference (IV, Fixed, 95% CI) 2.83 [0.18, 5.49]
4.2 Placebo 2 32 Mean Difference (IV, Fixed, 95% CI) -0.52 [-2.85, 1.82]
5 Pain free walking distance (m) 6 322 Mean Difference (IV, Fixed, 95% CI) 82.19 [71.73, 92.65]
6 Maximum walking distance (m) 6 391 Mean Difference (IV, Fixed, 95% CI) 113.20 [94.96, 131.
43]
7 Amputation 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 2. Exercise regimen compared with surgery
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximal walking time (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Maximum walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Ankle brachial pressure index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Peak exercise calf blood flow
(ml/100 ml/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Amputation 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6 Mortality 2 219 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.25, 2.17]
Comparison 3. Exercise regimen compared with angioplasty
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximal walking time (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Ankle brachial pressure index 2 52 Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.19, -0.10]
3 Pain free walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Maximum walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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5 Mortality 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 4. Exercise regimen compared with antiplatelet therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximal walking time (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Ankle brachial pressure index 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Peak exercise calf blood flow
(ml/100 ml/min)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 5. Exercise regimen compared with pentoxifylline therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Maximal walking time (minutes) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 6. Exercise regimen compared with iloprost therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain free walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Maximum walking distance (m) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Comparison 7. Exercise regimen compared with pneumatic foot and calf compression
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain free walking distance 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2 Maximum walking distance 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 1 Maximal
walking time (minutes).
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 1 Maximal walking time (minutes)
Study or subgroup Exercise Placebo/Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Usual care
Collins 2005 27 15.73 (4.46) 25 10.33 (4.67) 5.9 % 5.40 [ 2.91, 7.89 ]
Hiatt 1990 10 13.9 (3.5) 9 7.1 (2.9) 4.4 % 6.80 [ 3.92, 9.68 ]
Hiatt 1994 10 14.7 (7.3) 10 7.3 (2.7) 1.6 % 7.40 [ 2.58, 12.22 ]
Mika 2006 27 10.93 (1.32) 28 5.86 (1.28) 76.6 % 5.07 [ 4.38, 5.76 ]
Sanderson 2006 28 19.43 (8.44) 14 22.86 (11) 0.8 % -3.43 [ -9.99, 3.13 ]
Tsai 2002 27 12.5 (3.7) 26 7.6 (3.8) 8.9 % 4.90 [ 2.88, 6.92 ]
Subtotal (95% CI) 129 112 98.1 % 5.12 [ 4.51, 5.72 ]
Heterogeneity: Chi2 = 8.81, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 16.50 (P < 0.00001)
2 Placebo
Larsen 1966 7 8.17 (5.52) 7 3.04 (1.94) 1.9 % 5.13 [ 0.80, 9.46 ]
Subtotal (95% CI) 7 7 1.9 % 5.13 [ 0.80, 9.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Total (95% CI) 136 119 100.0 % 5.12 [ 4.51, 5.72 ]
Heterogeneity: Chi2 = 8.81, df = 6 (P = 0.18); I2 =32%
Test for overall effect: Z = 16.66 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.99), I2 =0.0%
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Analysis 1.2. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 2 Pain free
walking time (minutes).
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 2 Pain free walking time (minutes)
Study or subgroup Exercise Placebo/Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mika 2006 27 6.43 (1) 28 3.5 (0.47) 93.3 % 2.93 [ 2.51, 3.35 ]
Sanderson 2006 28 7.05 (6.14) 14 7.44 (7.38) 0.8 % -0.39 [ -4.88, 4.10 ]
Tsai 2002 27 6.2 (2.7) 26 3.2 (3.4) 5.9 % 3.00 [ 1.34, 4.66 ]
Total (95% CI) 82 68 100.0 % 2.91 [ 2.51, 3.31 ]
Heterogeneity: Chi2 = 2.10, df = 2 (P = 0.35); I2 =5%
Test for overall effect: Z = 14.20 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 1.3. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 3 Ankle brachial
pressure index.
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 3 Ankle brachial pressure index
Study or subgroup Exercise Placebo/Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Collins 2005 27 0.71 (0.22) 25 0.71 (0.17) 14.6 % 0.0 [ -0.11, 0.11 ]
Gardner 2002 28 0.67 (0.21) 24 0.72 (0.24) 10.8 % -0.05 [ -0.17, 0.07 ]
Hiatt 1990 10 0.71 (0.11) 9 0.62 (0.12) 15.3 % 0.09 [ -0.01, 0.19 ]
Hiatt 1994 10 0.53 (0.16) 8 0.61 (0.18) 6.5 % -0.08 [ -0.24, 0.08 ]
Hobbs 2005 16 0.71 (0.12) 18 0.7 (0.19) 14.8 % 0.01 [ -0.10, 0.12 ]
Hobbs 2006 7 0.7 (0.06) 7 0.68 (0.14) 13.0 % 0.02 [ -0.09, 0.13 ]
Tisi 1997 22 0.64 (0.14) 17 0.69 (0.12) 24.8 % -0.05 [ -0.13, 0.03 ]
Total (95% CI) 120 108 100.0 % -0.01 [ -0.05, 0.04 ]
Heterogeneity: Chi2 = 6.01, df = 6 (P = 0.42); I2 =0%
Test for overall effect: Z = 0.25 (P = 0.80)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 4 Peak exercise
calf blood flow (ml/100 ml/min).
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 4 Peak exercise calf blood flow (ml/100 ml/min)
Study or subgroup Exercise Placebo/Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Usual care
Gardner 2002 28 17.6 (6.56) 24 14.5 (6.52) 24.2 % 3.10 [ -0.46, 6.66 ]
Hiatt 1990 10 14.2 (3.2) 9 11.7 (5.3) 19.3 % 2.50 [ -1.49, 6.49 ]
Subtotal (95% CI) 38 33 43.5 % 2.83 [ 0.18, 5.49 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
2 Placebo
Dahllof 1974 10 16.9 (1.6) 8 18.1 (3.2) 52.1 % -1.20 [ -3.63, 1.23 ]
Larsen 1966 7 28 (9.63) 7 20.43 (5.86) 4.4 % 7.57 [ -0.78, 15.92 ]
Subtotal (95% CI) 17 15 56.5 % -0.52 [ -2.85, 1.82 ]
Heterogeneity: Chi2 = 3.91, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 0.43 (P = 0.66)
Total (95% CI) 55 48 100.0 % 0.94 [ -0.81, 2.69 ]
Heterogeneity: Chi2 = 7.40, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 3.45, df = 1 (P = 0.06), I2 =71%
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Analysis 1.5. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 5 Pain free
walking distance (m).
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 5 Pain free walking distance (m)
Study or subgroup Exercise Placebo/Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gardner 2002 28 402 (296) 24 203 (211) 0.6 % 199.00 [ 60.63, 337.37 ]
Hobbs 2005 16 181.7 (310) 18 63.3 (20.5) 0.5 % 118.40 [ -33.79, 270.59 ]
Hobbs 2006 7 115.2 (93.2) 7 136.7 (94) 1.1 % -21.50 [ -119.56, 76.56 ]
Jansen 1991 24 196 (26) 24 111 (13) 80.9 % 85.00 [ 73.37, 96.63 ]
Mika 2005 41 191.6 (94.8) 39 101.6 (50.1) 10.0 % 90.00 [ 57.00, 123.00 ]
Zwierska 2005 62 177 (117) 32 134 (78) 6.9 % 43.00 [ 3.27, 82.73 ]
Total (95% CI) 178 144 100.0 % 82.19 [ 71.73, 92.65 ]
Heterogeneity: Chi2 = 11.43, df = 5 (P = 0.04); I2 =56%
Test for overall effect: Z = 15.40 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 6 Maximum
walking distance (m).
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 6 Maximum walking distance (m)
Study or subgroup Exercise Placebo/Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gardner 2002 28 702 (302) 24 425 (274) 1.4 % 277.00 [ 120.38, 433.62 ]
Gelin 2001 73 247 (111) 76 261 (131) 21.9 % -14.00 [ -52.93, 24.93 ]
Hobbs 2005 16 248.6 (288.6) 18 122.1 (42) 1.6 % 126.50 [ -16.24, 269.24 ]
Hobbs 2006 7 254 (366.6) 7 271.7 (331.9) 0.2 % -17.70 [ -384.04, 348.64 ]
Jansen 1991 24 320 (50) 24 171 (25) 66.5 % 149.00 [ 126.64, 171.36 ]
Zwierska 2005 62 418 (179) 32 281 (129) 8.3 % 137.00 [ 73.89, 200.11 ]
Total (95% CI) 210 181 100.0 % 113.20 [ 94.96, 131.43 ]
Heterogeneity: Chi2 = 56.12, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 12.17 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 7 Amputation.
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 7 Amputation
Study or subgroup Exercise Placebo/Usual care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gelin 2001 0/88 2/89 0.20 [ 0.01, 4.15 ]
0.002 0.1 1 10 500
Exercise Placebo/usual care
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Analysis 1.8. Comparison 1 Exercise regimen compared with placebo/usual care, Outcome 8 Mortality.
Review: Exercise for intermittent claudication
Comparison: 1 Exercise regimen compared with placebo/usual care
Outcome: 8 Mortality
Study or subgroup Exercise Placebo/Usual care Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gelin 2001 5/88 4/89 1.26 [ 0.35, 4.55 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 2.1. Comparison 2 Exercise regimen compared with surgery, Outcome 1 Maximal walking time
(minutes).
Review: Exercise for intermittent claudication
Comparison: 2 Exercise regimen compared with surgery
Outcome: 1 Maximal walking time (minutes)
Study or subgroup Exercise Surgery
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lundgren 1989 21 6.89 (4.53) 23 8.55 (5.25) -1.66 [ -4.55, 1.23 ]
-4 -2 0 2 4
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Analysis 2.2. Comparison 2 Exercise regimen compared with surgery, Outcome 2 Maximum walking
distance (m).
Review: Exercise for intermittent claudication
Comparison: 2 Exercise regimen compared with surgery
Outcome: 2 Maximum walking distance (m)
Study or subgroup Exercise Surgery
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Gelin 2001 73 247 (111) 76 344 (169) -97.00 [ -142.74, -51.26 ]
-200 -100 0 100 200
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Analysis 2.3. Comparison 2 Exercise regimen compared with surgery, Outcome 3 Ankle brachial pressure
index.
Review: Exercise for intermittent claudication
Comparison: 2 Exercise regimen compared with surgery
Outcome: 3 Ankle brachial pressure index
Study or subgroup Exercise Surgery
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lundgren 1989 21 0.63 (0.14) 23 0.9 (0.19) -0.27 [ -0.37, -0.17 ]
-100 -50 0 50 100
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Analysis 2.4. Comparison 2 Exercise regimen compared with surgery, Outcome 4 Peak exercise calf blood
flow (ml/100 ml/min).
Review: Exercise for intermittent claudication
Comparison: 2 Exercise regimen compared with surgery
Outcome: 4 Peak exercise calf blood flow (ml/100 ml/min)
Study or subgroup Exercise Surgery
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lundgren 1989 21 19.7 (5.5) 23 22.4 (7.2) -2.70 [ -6.47, 1.07 ]
-10 -5 0 5 10
Surgery Exercise
Analysis 2.5. Comparison 2 Exercise regimen compared with surgery, Outcome 5 Amputation.
Review: Exercise for intermittent claudication
Comparison: 2 Exercise regimen compared with surgery
Outcome: 5 Amputation
Study or subgroup Exercise Surgery Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gelin 2001 0/88 1/87 0.33 [ 0.01, 7.98 ]
0.001 0.01 0.1 1 10 100 1000
Exercise Surgery
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Analysis 2.6. Comparison 2 Exercise regimen compared with surgery, Outcome 6 Mortality.
Review: Exercise for intermittent claudication
Comparison: 2 Exercise regimen compared with surgery
Outcome: 6 Mortality
Study or subgroup Exercise Surgery Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Gelin 2001 5/88 5/87 67.8 % 0.99 [ 0.30, 3.29 ]
Lundgren 1989 0/21 2/23 32.2 % 0.22 [ 0.01, 4.30 ]
Total (95% CI) 109 110 100.0 % 0.74 [ 0.25, 2.17 ]
Total events: 5 (Exercise), 7 (Surgery)
Heterogeneity: Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
0.1 0.2 0.5 1 2 5 10
Exercise Surgery
Analysis 3.1. Comparison 3 Exercise regimen compared with angioplasty, Outcome 1 Maximal walking
time (minutes).
Review: Exercise for intermittent claudication
Comparison: 3 Exercise regimen compared with angioplasty
Outcome: 1 Maximal walking time (minutes)
Study or subgroup Exercise Angioplasty
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Creasy 1990 16 6.2 (2) 20 2.9 (1.1) 3.30 [ 2.21, 4.39 ]
-10 -5 0 5 10
Angioplasty Exercise
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Analysis 3.2. Comparison 3 Exercise regimen compared with angioplasty, Outcome 2 Ankle brachial
pressure index.
Review: Exercise for intermittent claudication
Comparison: 3 Exercise regimen compared with angioplasty
Outcome: 2 Ankle brachial pressure index
Study or subgroup Exercise Angioplasty
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Creasy 1990 16 0.7 (0.03) 20 0.75 (0.13) 57.6 % -0.05 [ -0.11, 0.01 ]
Hobbs 2006 7 0.7 (0.06) 9 0.98 (0.08) 42.4 % -0.28 [ -0.35, -0.21 ]
Total (95% CI) 23 29 100.0 % -0.15 [ -0.19, -0.10 ]
Heterogeneity: Chi2 = 24.87, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 6.47 (P < 0.00001)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Angioplasty Exercise
Analysis 3.3. Comparison 3 Exercise regimen compared with angioplasty, Outcome 3 Pain free walking
distance (m).
Review: Exercise for intermittent claudication
Comparison: 3 Exercise regimen compared with angioplasty
Outcome: 3 Pain free walking distance (m)
Study or subgroup Exercise Angioplasty
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hobbs 2006 7 115.2 (93.2) 9 658 (403.7) -542.80 [ -815.43, -270.17 ]
-1000 -500 0 500 1000
Angioplasty Exercise
46Exercise for intermittent claudication (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Exercise regimen compared with angioplasty, Outcome 4 Maximum walking
distance (m).
Review: Exercise for intermittent claudication
Comparison: 3 Exercise regimen compared with angioplasty
Outcome: 4 Maximum walking distance (m)
Study or subgroup Exercise Angioplasty
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hobbs 2006 7 254 (366.6) 9 690.6 (364.7) -436.60 [ -797.88, -75.32 ]
-1000 -500 0 500 1000
Angioplasty Exercise
Analysis 3.5. Comparison 3 Exercise regimen compared with angioplasty, Outcome 5 Mortality.
Review: Exercise for intermittent claudication
Comparison: 3 Exercise regimen compared with angioplasty
Outcome: 5 Mortality
Study or subgroup Exercise Angioplasty Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Creasy 1990 6/26 4/30 1.73 [ 0.55, 5.47 ]
0.1 0.2 0.5 1 2 5 10
Exercise Angioplasty
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Analysis 4.1. Comparison 4 Exercise regimen compared with antiplatelet therapy, Outcome 1 Maximal
walking time (minutes).
Review: Exercise for intermittent claudication
Comparison: 4 Exercise regimen compared with antiplatelet therapy
Outcome: 1 Maximal walking time (minutes)
Study or subgroup Exercise Antiplatelet therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mannarino 1991 10 4.51 (1.06) 10 3.45 (1.01) 1.06 [ 0.15, 1.97 ]
-10 -5 0 5 10
Antiplatelet Exercise
Analysis 4.2. Comparison 4 Exercise regimen compared with antiplatelet therapy, Outcome 2 Ankle
brachial pressure index.
Review: Exercise for intermittent claudication
Comparison: 4 Exercise regimen compared with antiplatelet therapy
Outcome: 2 Ankle brachial pressure index
Study or subgroup Exercise Antiplatelet therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mannarino 1991 10 0.68 (0.24) 10 0.68 (0.27) 0.0 [ -0.22, 0.22 ]
-10 -5 0 5 10
Antiplatelet Exercise
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Analysis 4.3. Comparison 4 Exercise regimen compared with antiplatelet therapy, Outcome 3 Peak exercise
calf blood flow (ml/100 ml/min).
Review: Exercise for intermittent claudication
Comparison: 4 Exercise regimen compared with antiplatelet therapy
Outcome: 3 Peak exercise calf blood flow (ml/100 ml/min)
Study or subgroup Exercise Antiplatelet therapy
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Mannarino 1991 10 10.68 (0.34) 10 8.5 (3.95) 2.18 [ -0.28, 4.64 ]
-10 -5 0 5 10
Antiplatelet Exercise
Analysis 5.1. Comparison 5 Exercise regimen compared with pentoxifylline therapy, Outcome 1 Maximal
walking time (minutes).
Review: Exercise for intermittent claudication
Comparison: 5 Exercise regimen compared with pentoxifylline therapy
Outcome: 1 Maximal walking time (minutes)
Study or subgroup Exercise Pentoxifylline
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Ciuffetti 1994 15 3.15 (0.4) 15 3.6 (0.08) -0.45 [ -0.66, -0.24 ]
-4 -2 0 2 4
Pentoxifylline Exercise
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Analysis 6.1. Comparison 6 Exercise regimen compared with iloprost therapy, Outcome 1 Pain free walking
distance (m).
Review: Exercise for intermittent claudication
Comparison: 6 Exercise regimen compared with iloprost therapy
Outcome: 1 Pain free walking distance (m)
Study or subgroup Exercise Iloprost
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Arosio 2001 12 344.5 (293.6) 12 155.8 (87.4) 188.70 [ 15.38, 362.02 ]
-1000 -500 0 500 1000
Iloprost Exercise
Analysis 6.2. Comparison 6 Exercise regimen compared with iloprost therapy, Outcome 2 Maximum
walking distance (m).
Review: Exercise for intermittent claudication
Comparison: 6 Exercise regimen compared with iloprost therapy
Outcome: 2 Maximum walking distance (m)
Study or subgroup Exercise Iloprost
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Arosio 2001 12 598 (375.4) 12 401.2 (324.1) 196.80 [ -83.80, 477.40 ]
-1000 -500 0 500 1000
Iloprost Exercise
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Analysis 7.1. Comparison 7 Exercise regimen compared with pneumatic foot and calf compression,
Outcome 1 Pain free walking distance.
Review: Exercise for intermittent claudication
Comparison: 7 Exercise regimen compared with pneumatic foot and calf compression
Outcome: 1 Pain free walking distance
Study or subgroup Exercise
Pneumatic
compres-
sion
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kakkos 2005 12 92.9 (39.8) 13 253.2 (510.8) -160.30 [ -438.88, 118.28 ]
-1000 -500 0 500 1000
Pneumatic compression Exercise
Analysis 7.2. Comparison 7 Exercise regimen compared with pneumatic foot and calf compression,
Outcome 2 Maximum walking distance.
Review: Exercise for intermittent claudication
Comparison: 7 Exercise regimen compared with pneumatic foot and calf compression
Outcome: 2 Maximum walking distance
Study or subgroup Exercise
Pneumatic
compres-
sion
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kakkos 2005 12 417.1 (329.8) 13 479 (500) -61.90 [ -391.59, 267.79 ]
-1000 -500 0 500 1000
Pneumatic compression Exercise
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A D D I T I O N A L T A B L E S
Table 1. Functional status and Quality of life data (QoL)
Study Measure reported Effect reported
Collins Walking impairment ques-
tionnaire (WIQ) - perceived
distance and walking speed,
Rand Short form 36 (SF-36)
- perceived physical function
Exercise significant improve-
ment in physical compo-
nent summary score of SF-
36 than usual care
Gardner Peripheral arterial disease
physical activity recall, Min-
nesota Leisure Time Phys-
ical Activity Questionnaire
- daily physical activity, ac-
celerometer measured free
living daily activity, walk-
ing impairment question-
naire (WIQ), MOS SF-36
No change in self-reported
physical activity, or ambula-
tion assessed by WIQ. Ac-
celerometer measured free
living daily activity increased
in exercise group
Gelin Health-related QoL, QoL
overall
Exercise not superior to in-
vasive therapy on any QoL,
and superior to no treatment
on only one dimension. In-
vasive therapy significantly
greater improvements than
training on aspects of physi-
cal functioning and walking
related symptoms
Kakkos Short-form 36 (SF 36),
walking impairment ques-
tionnaire (WIQ), intermit-
tent claudication question-
naire (ICQ)
Pneumatic compression im-
proved ICQ score and speed
score of WIQ signigicantly,
exercise improved the WIQ
claudication severity score
significantly
Tisi Nottingham Health Profile
(NHP)
Exercise greater improve-
ment in subjective health
than angioplasty
Tsai Self-reported ambulatory
ability, perceived health-re-
lated quality of life, walking
impairment questionnaire
physical function
bodily pain
role limitation physical and
emotional
Perception of QoL increased
significantly in the exercise
group compared to usual
care
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Table 1. Functional status and Quality of life data (QoL) (Continued)
general health
mental health
social function
vitality
A P P E N D I C E S
Appendix 1. Search strategy for CENTRAL in The Cochrane Library
#1 MeSH descriptor Arterial Occlusive Diseases explode all trees
#2 MeSH descriptor Peripheral Vascular Diseases explode all trees
#3 peripheral near (vascular or arter*) or atherosclerosis or arteriosclerosis or PVD or PAOD or PAD
#4 arter* near occlus*
#5 obstruct* near arter*
#6 MeSH descriptor Intermittent Claudication explode all trees
#7 claudica*
#8 limb* near isch*
#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
#10 MeSH descriptor Exercise explode all trees
#11 MeSH descriptor Exercise Therapy explode all trees
#12 walk* or runni* or exerc* or train* or treadmill
#13 activi*
#14 (#10 OR #11 OR #12 OR #13)
#15 (#9 AND #14)
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WH A T ’ S N E W
Last assessed as up-to-date: 7 April 2008.
Date Event Description
18 June 2008 New search has been performed 12 new trials considered. Conclusions confirm the find-
ings of the previous review
29 April 2008 New citation required but conclusions have not changed Two new authors.
8 April 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 2, 1997
Review first published: Issue 1, 1998
Date Event Description
25 October 1999 New citation required but conclusions have not
changed
Substantive update
17 June 1998 New citation required and minor changes After consultation with GCL, original November 1997
version substituted for June 1998 ’update’ as latter was
an incorrect version. Some phrasing changed in June
1998, no changes to figures so earlier version more ap-
propriate. Edited abstract added too, 24.2.99
C O N T R I B U T I O N S O F A U T H O R S
Lorna Watson: selected trials, assessed quality, extracted data and revised text of review.
Brian Ellis: selected trials, assessed quality and extracted data.
Gillian Leng checked the content of the updated review.
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D E C L A R A T I O N S O F I N T E R E S T
None known
S O U R C E S O F S U P P O R T
Internal sources
• The University of Edinburgh, UK.
External sources
• The Chief Scientist Office, Scottish Executive Health Directorates, The Scottish Government, UK.
• The British Heart Foundation, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Exercise Therapy [∗methods]; Intermittent Claudication [∗therapy]; Randomized Controlled Trials as Topic; Walking
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